Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Neutrexin

(trimetrexate glucuronate)

Phase 2Small molecule

WWest Japan Thoracic Oncology Group

Neutrexin is one of 117 small molecule programs targeting Osteosarcoma. It is currently in Phase 2.

4

Indications

17

Total Trials

0

Active Trials

116

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

OsteosarcomaActive, not recruiting

PneumoniaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

OsteosarcomaPhase 2

Active, not recruiting

PneumoniaPreclinical

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

Vectibix

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Erbitux

SU5416

Cyramza

Azulfidine

Innohep

Alnylam Pharmaceuticals

Cecon

MMcGuff Pharmaceuticals, Inc.

Investigator's Choice Chemotherapy

QL1706

Qilu Pharmaceutical Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia12 trials

Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001014·302 enrolled

A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000998·50 enrolled

A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate With Leucovorin Protection for Patients With Pneumocystis Carinii Pneumonia.

Completed·UU.S. Bioscience·N/A·NCT00002102

Show 9 more trials

Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000730·240 enrolled

A Treatment Protocol for the Use of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia and Serious Intolerance to Approved Therapies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001016

Randomized Phase I Study of Trimetrexate Glucuronate (TMTX) With Leucovorin (LCV) Protection Plus Dapsone Versus Trimethoprim / Sulfamethoxazole (TMP/SMX) for Treatment of Moderately Severe Episodes of Pneumocystis Carinii Pneumonia

Completed·UU.S. Bioscience·Phase 1·NCT00002120·20 enrolled

A Study of Trimetrexate With Leucovorin Rescue for AIDS Patients Who Are Refractory to Standard Therapies for Pneumocystis Carinii Pneumonia

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000724

A Study of Trimetrexate Plus Leucovorin in Children With Pneumocystis Carinii Pneumonia

Completed·UU.S. Bioscience·N/A·NCT00002317

Comparison of Trimetrexate Plus Leucovorin Calcium Rescue Versus Sulfamethoxazole-Trimethoprim in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00001013·364 enrolled

An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000714

A Compassionate Treatment Protocol for the Use of Trimetrexate Glucuronate (Neutrexin) With Leucovorin Protection for European Adult Patients (>= 13 Years Old) With Pneumocystis Carinii Pneumonia

Completed·UU.S. Bioscience·N/A·NCT00002103

A Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP)

Completed·UU.S. Bioscience·N/A·NCT00002434

Osteosarcoma2 trials

Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00119301·18 enrolled

Combination Chemotherapy and Surgery in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003776

Cancer of the Pancreas1 trial

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas

Completed·UUniversity of Southern California·Phase 2·NCT00002955·21 enrolled

Metastatic Colorectal Cancer1 trial

Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Completed·GGrupo Oncologico Cooperativo del Sur·Phase 2·NCT00003446

Acute Lymphoblastic Leukemia1 trial

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002738·25 enrolled

Regulatory

FDA Approval Timeline[4]

Dec 17, 1993

NEUTREXIN

NDA NDA020326

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for trimetrexate glucuronate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — trimetrexate glucuronate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for trimetrexate glucuronate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020326). U.S. Food & Drug Administration.
[5]
SEC EDGAR — West Japan Thoracic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWest Japan Thoracic Oncology Group

Related News